Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

1
100
0
2

Year Published

2019
2019
2022
2022

Publication Types

Select...
8

Relationship

0
8

Authors

Journals

citations
Cited by 99 publications
(103 citation statements)
references
References 24 publications
1
100
0
2
Order By: Relevance
“…Patients with Stage 1 or 2, HER2 + BCs may consider ado-trastuzumab emtansine (± pertuzumab) with comparable efficacy to chemotherapy/trastuzumab-based regimens in either neoadjuvant or adjuvant settings (Priority B2) to minimize neutropenia, visits, and steroid-use [30,31]. Adjuvant trastuzumab-based therapy may be shortened from 12 to 6 months without affecting outcomes in selected patients (Priority B3) [32,33].…”
Section: Invasive Bc-early Stagementioning
confidence: 99%
“…Patients with Stage 1 or 2, HER2 + BCs may consider ado-trastuzumab emtansine (± pertuzumab) with comparable efficacy to chemotherapy/trastuzumab-based regimens in either neoadjuvant or adjuvant settings (Priority B2) to minimize neutropenia, visits, and steroid-use [30,31]. Adjuvant trastuzumab-based therapy may be shortened from 12 to 6 months without affecting outcomes in selected patients (Priority B3) [32,33].…”
Section: Invasive Bc-early Stagementioning
confidence: 99%
“…The larger, phase 3 PHARE (Protocol for Herceptin as Adjuvant Therapy With Reduced Exposure) and PERSEPHONE (6 versus 12 months of adjuvant trastuzumab for HER2‐positive early breast cancer) trials in HER2‐positive, early breast cancer had similar designs and assessed the same clinical endpoints . The final PHARE analysis, with a median follow‐up of 7.5 years, failed to show that 6 months of trastuzumab was noninferior to 12 months of trastuzumab; the frequency of cardiac events was lower in the 6‐month arm.…”
Section: Optimizing Schedules For Cancer Therapymentioning
confidence: 99%
“…Pharmaceutical companies are not typically interested in sponsoring trials for neglected cancers (eg, liver, brain) or for investigating de‐escalation of established cancer medicines that are no longer under patent . PHARE (described above) was funded by the French National Cancer Institute, whereas the International Duration of Evaluation of Adjuvant Therapy (IDEA) analysis of colon cancer was funded by various noncommercial grants …”
Section: Optimizing Cancer Medicine Researchmentioning
confidence: 99%
See 1 more Smart Citation
“…In the past decade, multiple trials, including two phase 3 randomised trials, 7,8 one three-group phase 2 trial, 2 and two single-group phase 2 trials, 9,10 have found an excellent therapeutic index associated with novel, anthracycline-free regimens. Additionally, five studies [11][12][13][14][15][16] evaluated whether a shorter duration of trastuzumab is non-inferior to the standard year. Non-inferiority could not be concluded in the first four studies; [11][12][13][14] thus, the debate appeared to be closed.…”
Section: Is the Duration Of Adjuvant Trastuzumab Debate Still Clinicamentioning
confidence: 99%